- Email: [email protected]
Prethrombotic state in patients with myocardial infarction?
MONDAYJUNE25 - THURSDAYJUNE28 1990 115 295 Transcutaneous transport of LMW-heparln VXHL J, OlTM, ZIMMERMANN E Physiologiwhes Institut II der WestjUschen Wdhelnw Universitiit, Miinster, FRG The question as to whether heparin is able to permeate human skin arouses controversy among dermatological experts. Some scientists claim that heparin enhances the resorption of subcutaneous hematoma, improve endothelial proliferation by inducing capillary growth and, therefore, enhancing blood supply to tissues and organs. Another controversial point in current research is the antiphlogistic effect of heparin on cutaneous inflammation. To investigate the latter effects we used a low molecular weight heparin supplied as an ointment with 30,000 units/100 g and were able to show at first that heparin permeates human skin in vitro as well as in vivo. Applying heparin topically in vivo we found an increase of systemic anti-factor IIa-activity in the
296 Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low molecular weight heparin MONREAL M, MONREAL L, LAVINS, LAFOZ E, ANGLkS AM, MONASTERIO J Unit of Experimental i’kombosis, Universidad Autonoma de Barcelona, Spain
test persons plasma. In a second experiments we produced hematoma by injecting blood subcutaneously in order to test the effects of heparin on the resorption of hemoglobin derivatives by measuring the skin colour with a specific reflexion photometer. Finally we induced erythema by UVA radiation and compared the visible changes of inflammation between the placebo and heparin treated groups. The results of our experiments demonstrate that topically applied heparin has significant local effects although its systemic potency turned out to be poor.
0.748kO.026 g/ml; p=O.O02). By contrast, bone density in Fragmin-treated rats was not significantly lower than in control rats (1305+0.037 g/ml; p=NS). The decrease in ash contents was not as pronounced as with UFH (0.715+0.042 g/ml). Our findings suggest that fragmin may have a lower osteopenic effect than that of conventional heparin. If proven in humans, Fragmin could be a good alternative to oral anticoagulants in those patients with contraindications to coumarin.
In an animal model we have compared the effect of a high-dose of conventional heparin (2 IU/g SC twice a day) and a low-molecular weight heparin (Fragmin, 1 anti-Xa U/g once a day) with that of placebo on the mineral bone mass in the femur of rats. After 33 days of treatment no differences were found in the weight of the femur. But heparin-treated rats exhibited a lower density (1249+0.046 g/ml) as compared with that in control rats (1324a0.039 g/ml; p=0.00007). Similarly, statistically significant differences have been found in ash contents (0.698+0.036 vs
297 Prethrombotic state in patients with myocardiai infarction? KIRCHHOF B, ETSCHEID B Depart. Internal Med. St. Josef Hospital, Engelskirchen, FRG In order to look for signs of prethrombotic state in patients with acute myocardial infarction (AMI) a set of lab tests was performed. Each test was done after admission (time 0), 3 and 6 hours later and once daily for 6 days in samples from 40 patients, 19 undergoing (A) and 21 not undergoing (B) thrombolytic therapy. The tests were: PTZ, TT, PIT, platelet count, fibrinogen (clotting method), AT III, plasminogen and antiplasmin (chromogenic assay) as well as thrombinAT III-complex (TAT, ELISA) and D-D-neoantigen (DD, latex agglutination). Patients of group A came to admission 115 min and those of group B 310 min after onset of symptoms. There were no significant differences in the results of
group A and B. Most values were near the means of normal ranges. But AT III went down from 98% at time 0 to 82% at day 4 in both groups. TAT was slightly elevated at time 0 (8.4 ,&l) and went down to 3.5&l at day 4. The DD was positive in 11 cases at time 0 and remained positive at day 4 and 5. We conclude that there are some signs indicating a weak prethrombotic state in patients with AMI, which could not be proved really.
296 Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low molecular weight heparin MONREAL M, MONREAL L, LAVINS, LAFOZ E, ANGLkS AM, MONASTERIO J Unit of Experimental i’kombosis, Universidad Autonoma de Barcelona, Spain
test persons plasma. In a second experiments we produced hematoma by injecting blood subcutaneously in order to test the effects of heparin on the resorption of hemoglobin derivatives by measuring the skin colour with a specific reflexion photometer. Finally we induced erythema by UVA radiation and compared the visible changes of inflammation between the placebo and heparin treated groups. The results of our experiments demonstrate that topically applied heparin has significant local effects although its systemic potency turned out to be poor.
0.748kO.026 g/ml; p=O.O02). By contrast, bone density in Fragmin-treated rats was not significantly lower than in control rats (1305+0.037 g/ml; p=NS). The decrease in ash contents was not as pronounced as with UFH (0.715+0.042 g/ml). Our findings suggest that fragmin may have a lower osteopenic effect than that of conventional heparin. If proven in humans, Fragmin could be a good alternative to oral anticoagulants in those patients with contraindications to coumarin.
In an animal model we have compared the effect of a high-dose of conventional heparin (2 IU/g SC twice a day) and a low-molecular weight heparin (Fragmin, 1 anti-Xa U/g once a day) with that of placebo on the mineral bone mass in the femur of rats. After 33 days of treatment no differences were found in the weight of the femur. But heparin-treated rats exhibited a lower density (1249+0.046 g/ml) as compared with that in control rats (1324a0.039 g/ml; p=0.00007). Similarly, statistically significant differences have been found in ash contents (0.698+0.036 vs
297 Prethrombotic state in patients with myocardiai infarction? KIRCHHOF B, ETSCHEID B Depart. Internal Med. St. Josef Hospital, Engelskirchen, FRG In order to look for signs of prethrombotic state in patients with acute myocardial infarction (AMI) a set of lab tests was performed. Each test was done after admission (time 0), 3 and 6 hours later and once daily for 6 days in samples from 40 patients, 19 undergoing (A) and 21 not undergoing (B) thrombolytic therapy. The tests were: PTZ, TT, PIT, platelet count, fibrinogen (clotting method), AT III, plasminogen and antiplasmin (chromogenic assay) as well as thrombinAT III-complex (TAT, ELISA) and D-D-neoantigen (DD, latex agglutination). Patients of group A came to admission 115 min and those of group B 310 min after onset of symptoms. There were no significant differences in the results of
group A and B. Most values were near the means of normal ranges. But AT III went down from 98% at time 0 to 82% at day 4 in both groups. TAT was slightly elevated at time 0 (8.4 ,&l) and went down to 3.5&l at day 4. The DD was positive in 11 cases at time 0 and remained positive at day 4 and 5. We conclude that there are some signs indicating a weak prethrombotic state in patients with AMI, which could not be proved really.